skip to content
Primary navigation


Drug - Zontivity™ (voraxapar) [Merck Sharp & Dohme Corp]

November 2014

Therapeutic Area - Platelet aggregation inhibitors

Approval criteria

  • Patient must have a history of myocardial infarction or peripheral artery disease AND
  • Patient must also be taking concurrent therapy with aspirin or clopidogrel AND
  • Patient has no previous medical history of stroke, TIA or intracranial hemorrhage


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top